沈阳治腋臭去沈阳那个医院(沈阳治疗痤疮的大概价格) (今日更新中)

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

THE HAGUE, June 1(Xinhua) -- Five people in the Netherlands have been sickened with an unusual strain of the E. coli bacteria, the institute for public health (RIVM) reported Wednesday.Of the five patients, four also suffered from intestinal problems and renal failure. The five who are infected all had recently been in Germany.The patients were infected with enterohaemorrhagic E.coli, or EHEC, a particularly deadly strain of the common bacteria found in the digestive systems of cows, humans and other mammals.The outbreak has hit at least eight European countries but virtually all of the sick people either live in Germany or recently traveled there.Medical authorities appeared no closer to discovering either the source of the infection or the mystery at the heart of the outbreak: why the unusual strain of the E. coli bacteria appears to be causing so many cases of hemolytic uremic syndrome, which attacks the kidneys and can cause seizures, strokes and comas.Earlier this week German researchers showed that Dutch cucumbers were not the cause of the contamination."It is essential to quickly find the source, as long as that is not found, the contamination can spread. It's a very aggressive bacteria and many people are seriously ill," a RIVM spokesman said.

BEIJING, Aug. 13 (Xinhua) -- The quality of the products China exported to the European Union (EU) improved during the first half of this year due to strict quality control measures, according to quality control authorities.The number of quality complaints made by the EU regarding Chinese imports declined by 45 percent in the first half of 2011, according to the General Administration of Quality Supervision, Inspection and Quarantine (AQSIQ).The administration attributed the improved quality to its nationwide crackdown on counterfeited and substandard products.The administration launched a nationwide quality checkup in the first half of this year. Of the 4,815 batches of products that the quality control authorities checked between January and June, just 9.4 percent failed quality tests, 1.7 percentage points lower than that of the same period of last year, according to the administration.A total of 218,000 counterfeiting cases have been investigated so far this year, involving goods worth a total of 9.5 billion yuan (1.49 billion U.S. dollars), the administration said.

BEIJING, Aug. 15 (Xinhua) -- Scientists in a lab with Daya Bay Nuclear Power Station in southern Guangdong Province have found neutrino through two detecting instruments, which is likely to provide clues to solving the mystery of why there is more matter than antimatter in the universe.The Institute of High Energy Physics with the Chinese Academy of Sciences on Monday announced the breakthrough that was achieved by more than 250 researchers from six countries and regions.The two neutrino detectors are installed underground 360 meters away from the nuclear plant at a depth of 100 meters.Scientists believe that matter and antimatter were created in equal amounts during the Big Bang, but the disappearance of antimatter remains a mystery.Neutrino is an elementary particle that is able to pass through ordinary matter almost unaffected, which makes it extremely difficult to detect.Located in Shenzhen, a city neighboring Hong Kong, the Daya Bay Nuclear Power Station commenced operation in 1993.Scientists from the Chinese Academy of Sciences and the U.S.-based Brookhaven National Laboratory and the Lawrence Berkeley National Laboratory started the underground neutrino experiment in 2006.Kam-Biu Luk, spokesman for the laboratory, said that the results of the experiment would further shed light on the evolution of basic matter after the Big Bang.The neutrino experiment in the Daya Bay is one of the largest cooperation projects with regards to basic research between China and the United States.Among the participants of the experiment are Russia, Czech Republic, and China's Hong Kong and Taiwan regions.

WASHINGTON, Aug. 2 (Xinhua) -- A new study has identified the recent emergence of a multidrug-resistant strain of Salmonella that has a high level resistance to ciprofloxacin, a common treatment for severe Salmonella infections. The study was published on-line Tuesday in The Journal of Infectious Diseases.Francois-Xavier Weill at the Pasteur Institute in France and colleagues studied information from national surveillance systems in France, England and Wales, Denmark, and the United States. The data showed that a multidrug-resistant strain of Salmonella, known as S. Kentucky, infected 489 patients in France, England and Wales, and Denmark between 2000 and 2008. In addition, researchers reported that the first infections were acquired mainly in Egypt between 2002 and 2005, while since 2006 the infections have also been acquired in various parts of Africa and the Middle East. The absence of reported international travel in approximately 10 percent of the patients suggests that infections may have also occurred in Europe through consumption of contaminated imported foods or through secondary contaminations.In this study, multidrug-resistant S. Kentucky was isolated from chickens and turkeys from Ethiopia, Morocco, and Nigeria, suggesting that poultry is an important agent for infection. The common use of fluoroquinolones in chicken and turkey production in Nigeria and Morocco may have contributed to this rapid spread, according to the researchers.This study highlights the importance of public health surveillance in a global food system. The investigators reported that they will continue to monitor this multidrug-resistant strain as well as help strengthen the capacities of national and regional laboratories in the surveillance of Salmonella and other major foodborne pathogens through the World Health Organization Global Foodborne Infections Network.Salmonella infection represents a major public health problem worldwide. An estimated 1.7 million such infections occur in North America each year. More than 1.6 million cases were reported between 1999 and 2008 in 27 European countries. Although most Salmonella infections produce only mild gastroenteritis, elderly and immunocompromised patients are especially at risk for life- threatening infections. These cases are typically treated with antimicrobials called fluoroquinolones, such as ciprofloxacin.

来源：资阳报